Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) EBITDA (2018 - 2026)

10x Genomics' EBITDA history spans 8 years, with the latest figure at -$19.5 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 60.79% to -$19.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$61.0 million, a 68.65% increase, with the full-year FY2025 number at -$61.0 million, up 68.65% from a year prior.
  • EBITDA hit -$19.5 million in Q4 2025 for 10x Genomics, up from -$32.2 million in the prior quarter.
  • Over the last five years, EBITDA for TXG hit a ceiling of $30.1 million in Q2 2025 and a floor of -$94.8 million in Q3 2023.
  • Historically, EBITDA has averaged -$37.3 million across 5 years, with a median of -$40.7 million in 2022.
  • Biggest five-year swings in EBITDA: crashed 471.61% in 2022 and later skyrocketed 172.18% in 2025.
  • Tracing TXG's EBITDA over 5 years: stood at -$18.6 million in 2021, then dropped by 24.03% to -$23.1 million in 2022, then crashed by 138.95% to -$55.2 million in 2023, then rose by 9.69% to -$49.8 million in 2024, then skyrocketed by 60.79% to -$19.5 million in 2025.
  • Business Quant data shows EBITDA for TXG at -$19.5 million in Q4 2025, -$32.2 million in Q3 2025, and $30.1 million in Q2 2025.